Clinical trial
A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma
NCT00415155 · Eli Lilly and Company, Industry · Withdrawn
Key facts
| NCT number | NCT00415155 |
|---|---|
| Title | A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma |
| Official title | An Open Label, Single Arm, Phase 1b/2 Study With Pharmacokinetic Sampling to Evaluate LY2181308 in Patients With Advanced Hepatocellular Carcinoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma |
| Intervention type | Drug |
| Interventions | LY2181308 |
| Enrollment | 60 |
| Start date | Aug 1, 2008 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | Dec 22, 2006 |
| Last update posted | Aug 29, 2008 |
| Countries | France, Germany, Spain, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: